CRISPR/Cas9 genome editing of CCR5 combined with C

CRISPR/Cas9 genome editing of CCR5 combined with C46 HIV-1 fusion inhibitor for cellular resistant to R5 and X4 tropic HIV-1

From May ‘24. Hope we can get across the finish line soon.

https://www.nature.com/articles/s41598-024-61626-x

“We found that the two doses of CRISPR/Cas9 RNP complex showed an approximately range between 77.50 and 98.40% cell viability after nucleofection, as determined in 7AAD- cell population analysis by flow cytometry (Fig. 1c and Supplementary information 3). The dose dependence of the CRISPR/Cas9 RNP complex was shown in MT4CCR5 cells nucleofected with the first dose of RNP complex, which composed of 6 µg of in-house Cas9 protein and 2 µg of each sgRNA displayed a CCR5 expression level of 10.43% ± 0.15 (mean ± SD), representing an 89.37% reduction compared to the mock control (99.80% ± 0.00, mean ± SD). Conversely, cells receiving the second dose of RNP complex, comprised of 10 µg of in-house Cas9 protein and 4 µg of each sgRNA exhibited a CCR5 expression level of 1.91% ± 0.13 (mean ± SD), corresponding to a 97.89% reduction in CCR5 expression (Fig. 1c and Supplementary Information 3)”